[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"female-pattern-baldness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:female-pattern-baldness":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,73,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100507556","phase-3-evaluation-of-efficacy-and-safety-of-oral-minoxidil-1-mg-in-female-androgenetic-alopecia-100507556",false,"NCT05888922","Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia","Inclusion Criteria:\n\n1. Female patients aged 18 years or older, with general good health (i.e., with no history of cardiovascular disorders, or any other clinically significant disease).\n2. Diagnosed with FAGA, based on a discernible decrease in hair density (Sinclair Scale 2-4) in the centroparietal area of the scalp.\n3. Hair color of patient provides sufficient contrast with the scalp and as confirmed by TrichoLab Virtual Tattoo® technology at Screening\u002FVisit 1.\n4. A personally signed and dated informed consent document indicating that the patient, has been informed of all pertinent aspects of the clinical trial.\n5. Negative serum pregnancy test at Visit 1\u002FScreening and negative urine pregnancy test at Visit 2\u002FBaseline for women of child-bearing potential (WOCBP).\n6. WOCBP must either be permanently sterile1 or agree to use a highly effective birth control method (failure rate ˂1% per year when used consistently and correctly) throughout the clinical trial and for at least 2 weeks after last administration of IPs.\n\n   Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive and planned to be continued throughout the clinical trial duration.\n7. Patients willing to maintain the same hairstyle (color and hair regimen) throughout the clinical trial. Hair length must remain of sufficient length to not affect determination of hair density and patient should discuss with clinical trial personnel before changing from Visit 2\u002FBaseline.\n8. Patient is willing to maintain the same depilatory habits and intervals regarding facial or body hair before each visit throughout duration of the clinical trial.\n9. Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical trial procedures, including daily e diary recordings by the patient using an own electronic device (e.g., tablet, smartphone, personal computer) and an internet connection during the clinical trial.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or known allergy to minoxidil or to any of the other components of the products.\n2. Pregnancy or pregnancy desire during the clinical trial.\n3. Breastfeeding\u002FNursing women.\n4. Any diagnosed treated or untreated hypertension (or blood pressure values \\>150 mmHg systolic \u002F \\>95 mmHg diastolic) as determined at Visit 1\u002FScreening, and\u002For history\u002Fsigns of known cardiovascular diseases (including but not limited to cardiac ischemia, congestive heart failure, cardiac arrhythmia), and patients with pathologies or punctual situations that might either be caused by or increase the risk of cardiac disorders.\n5. Patients with any dermatological disorders of the scalp in the target region at Visit 1\u002FScreening with the possibility of interfering with the application of the IPs or examination method, such as\n\n   1. Active moderate or severe seborrheic dermatitis under chronic treatment, abrasion, actinic keratosis, or inflammatory disorders, or\n   2. any local infection of the skin\u002Fsubcutaneous tissues of the head within the previous 3 months, or\n   3. any documented history of active atopic dermatitis or psoriasis in the scalp within the previous 6 months.\n   4. any other types of alopecia (e.g., alopecia areata or scarring alopecia) at any time point or diffuse telogen effluvium, trichotillomania, or other pathological hair loss conditions\u002Fdiseases other than AGA in the last 3 months at the discretion of the investigator).\n6. Patients who had hair transplant surgery at any time.\n7. Patients who had hair weaving, or any other hair extension methods within the last 6 months prior to Visit 2\u002FBaseline.\n8. Clinically significant abnormal laboratory values or ECG findings (if applicable) at Visit 1\u002FScreening indicative of physical illness, according to investigator assessment.\n9. Both creatinine and eGFR above upper limit of normal at Visit 1\u002FScreening.\n10. Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases that in the opinion of the investigator may interfere with the aim of the clinical trial.\n11. Patient has used any of the following topical preparations or procedures on the scalp:\n\n    1. Topical scalp treatments for hair growth, including minoxidil within the last 6 months prior to Visit 2\u002FBaseline; or hormone therapy, antiandrogens, or other agents that are known to affect hair growth within 12 weeks prior to Visit 2\u002FBaseline.\n    2. Topical scalp treatments that might have had ancillary effect on hair growth including, but not limited to, corticosteroids, pimecrolimus, and tacrolimus within the last 4 weeks prior to Visit 2\u002FBaseline.\n    3. Topical scalp over the counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene®, Nioxin®, Foltene®, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within the last 4 weeks prior to Visit 2\u002FBaseline.\n    4. Light or laser treatment or microneedling of scalp within the last 6 months prior to Visit 2\u002FBaseline.\n    5. Platelet rich plasma (PRP) procedure on the scalp within the last 6 months prior to Visit 2\u002FBaseline.\n12. Patient has used the following systemic medications or procedures:\n\n    1. Zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines, or other vasodilators or antihypertensive agents such as guanethidine and derivatives within the last 12 months prior to Visit 2\u002FBaseline.\n    2. Any 5 alpha reductase medications (i.e., dutasteride, finasteride \\[Propecia®, etc.\\] or similar product\\[s\\]) within the last 12 months prior to Visit 2\u002FBaseline.\n    3. Retinoid therapy within the last 6 months prior to Visit 2\u002FBaseline.\n    4. Beta blockers, anabolic steroids, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2\u002FBaseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable (defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2\u002FBaseline.\n    5. Drugs with antiandrogenic properties, such as flutamide, cimetidine, or ketoconazole within the last 6 months prior to Visit 2\u002FBaseline; bicalutamide within 2 months and spironolactone within 1 month prior to Visit 2\u002FBaseline. Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2\u002FBaseline and if used as contraceptive.\n    6. Minoxidil within the last 6 months prior to Visit 2\u002FBaseline.\n    7. Prostaglandins and derivates within the last 3 months prior to Visit 2\u002FBaseline. Topical and ocular prostaglandins and its derivates are allowed.\n    8. Biotin (\\>5 mg) within the last 4 weeks prior to Visit 2\u002FBaseline.\n    9. Previous radiation of the scalp and treatment with chemotherapy\u002Fsystemic cytotoxic agents at any timepoint.\n13. Participation in the evaluation of any investigational drugs within 30 days or 5 half lives (whichever is longer) prior to Visit 2\u002FBaseline, calculated from the first day of the month following the last visit of the previous clinical trial.\n14. History of drug and alcohol dependency.\n15. In the opinion of the investigator the patient should not participate in the clinical trial, e.g., due to probable non compliance or inability to understand the clinical trial and give adequately informed consent.\n16. Close affiliation with the investigator (e.g., a close relative) or persons working at the clinical trial centers or patient is an employee of sponsor.\n17. Patient is institutionalized because of legal or regulatory order.","FEMALE","18 Years",{"count":19,"type":20},520,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss.\n\nThe main questions to answer are to know about that minoxidil 1mg is as effective as minoxidil 2% topical solution (comparator product) and is more effective than placebo; and to ensure treatment with oral minoxidil is safe.\n\nParticipants will be assigned randomly to receive one of the following treatment combinations:\n\n* the test product (oral minoxidil 1 mg, once\u002Fday) and the vehicle solution (vehicle means it looks like the comparator product, but it does not contain an active ingredient, 2 times\u002Fday), or\n* the placebo tablet (placebo means it looks like the test product, but it does not contain an active ingredient, once\u002Fday) and the comparator product (2% minoxidil solution, 2 times\u002Fday), or\n* the placebo tablet (once\u002Fday) and the vehicle solution (2 times\u002Fday).\n\nThe clinical trial will take up to 36 weeks. During this time, patients will come to the clinical trial centre for 5 times for examinations and will be called by phone twice. At the visits, the following examinations will be performed: photos of the hair will be taken to determine hair density, assessment of changes in scalp hair growth, measurement of blood pressure, pulse, and body temperature, a physical examination, blood withdrawal to determine any abnormalities in the blood, urine sampling and analysis, performance of ECG, and evaluation of hypertrichosis (i.e., excessive hair growth over the body). Furthermore, patients will be asked daily whether they had experienced any side effects or took any new medications (or changed the dose of a known medication) or underwent any medical procedure. Also, women of childbearing potential must undergo pregnancy tests in blood and urine.",[26,27],"Androgenetic Alopecia","Female Pattern Baldness",[29,27,30,31],"Androgenetic alopecia","FAGA","Minoxidil","RECRUITING","2026-05-08",{"date":35,"type":36},"2026-05-12","ACTUAL",{"date":38,"type":36},"2024-10-17",{"date":40,"type":20},"2026-11",{"name":42,"class":43},"Industrial Farmacéutica Cantabria, S.A.","INDUSTRY",13,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100587256","1550nm-non-ablative-fractional-vs-1927nm-thulium-fractional-laser-for-the-treatment-of-female-pattern-hair-loss-100587256","NCT06926023","1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss","A Prospective, Randomized, Evaluator-blind, Clinical Trial Evaluating the 1550nm Non-ablative Fractional or 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss","Inclusion Criteria:\n\n1. Adult women aged 35-65 years\n2. Fitzpatrick skin types I-IV\n3. Presence of female pattern hair loss of the frontal or vertex of scalp (Sinclair (II-IV)\n4. Must be willing and can comply with all study protocols, including all treatment schedules, follow up visit, assessments, sign a photography release and ICF, and complete the entire course of the study\n5. Patients with gray hair roots must be willing to dye their gray hair within two weeks of the first appointment and the last 3-month follow-up visit to ensure consistency in evaluator assessments.\n6. No use of hair growth treatments or procedures within 6 months prior to enrollment (including hair supplements such as Nutrafol)\n7. Subjects in good general health based on investigator's judgment and medical history\n8. Negative urine pregnancy test result at the time of study entry\n9. Subjects will be of non-childbearing potential defined as:\n10. Having no uterus\n11. No menses for at least 12 months.\n12. Or;\n13. Subjects of childbearing potential must agree to use an effective method of birth control during the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. Acceptable forms of birth control below:\n14. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\n15. Intrauterine coil\n16. Bilateral tubal ligation\n17. Hysterectomy\n18. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)\n19. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).\n20. Vasectomized (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized partner).\n\nExclusion Criteria:\n\n1. No surgery, pregnancy, breast feeding, change in or addition of hormonal contraception in the last 6 months\n2. No history of iron deficiency anemia, vitamin D deficiency, or thyroid disease (hypothyroidism or hyperthyroidism or currently on thyroid supplementation)\n3. Use of scalp light or with laser treatment within the last 6 months.\n4. Use of topical or systemic drugs affecting hair growth within 6 months prior to enrollment (such as oral spironolactone, finasteride, oral or topical minoxidil, and supplements marketed for hair growth such as Nutrafol)\n5. Supplementation of oral tumeric\u002Fcurcumin\n6. History of hair transplant\n7. Systemic or scalp disease that may affect hair growth (Lupus, alopecia areata, folliculitis decalvans, psoriasis, scalp infection, seborrheic dermatitis, CCCA, telogen effluvium)\n8. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n9. Any uncontrolled systemic disease\n10. History of autoimmune connective tissue disease or thyroid disease.\n11. Current use of immunosuppressive medication.\n12. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n13. Active dermatitis, metal or other active implants, active infection in the proposed treatment area.\n14. Subjects with scarring in the treatment areas (scalp) Subjects with a history of keloids will be excluded.\n15. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease, history of Bell's Palsy, epilepsy, smoking, pregnancy, and lactation.\n16. Inability to following the comply with study protocols and regulations\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",true,"35 Years","65 Years",{"count":56,"type":20},10,[58],"NA","To evaluate the efficacy of either a 1550nm non-ablative fractional laser or a 1927nm thulium fractional laser in the treatment of female pattern hair loss (FPHL).",[27],"NOT_YET_RECRUITING","2025-04-11",{"date":64,"type":36},"2025-04-16",{"date":66,"type":20},"2025-05-01",{"date":68,"type":20},"2025-12-31",{"name":70,"class":71},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":79,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100554656","phase-3-clinical-study-of-da-002-and-da-005-as-a-treatment-for-hair-loss-100554656","NCT06501924","Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with androgenetic alopecia\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-002 or DA-005\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits","ALL",{"count":81,"type":20},516,[23],"The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).",[26,27,85],"Male Pattern Baldness","2024-12-17",{"date":88,"type":36},"2024-12-19",{"date":90,"type":20},"2025-01-15",{"date":92,"type":20},"2025-12-12",{"name":94,"class":43},"Applied Biology, Inc.",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":72},"100502577","phase-3-efficacy-and-safety-of-oma102-in-the-treatment-of-female-pattern-hair-loss-100502577","NCT05824065","Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss","Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss","GENERA","Inclusion Criteria:\n\n* Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;\n* Age greater than 18 and equal or under 50 years;\n* Confirmed diagnosis of female pattern hair loss, grade II to IV in Sinclair Scale;\n* Participants that are disposed to maintain the same hair color, style, approximate hair length throughout the Clinical Study.\n\nExclusion Criteria:\n\n* Any clinical or physical finding interpreted by the investigator as a risk to subject participation in the Clinical Study\n* History of alcohol or illicit drugs abuse in the last year;\n* Pregnant or breastfeeding women, who are planning to become pregnant or participants who have childbearing potential and are not using any reliable contraceptive method;\n* Allergy or sensibility to any knowing components of the formula;\n* Diagnosis of arterial hypertension;\n* History of vasovagal syncope;\n* Baseline systolic blood pressure lower than 90 mmHg and\u002For diastolic lower than 60 mmHg;\n* Diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmHg and\u002For diastolic equal or superior to 10 mmHg after 3 minutes in orthostatic position);\n* Body mass index (BMI) \\> 30 kg\u002Fm²;\n* Subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the Clinical Study;\n* History of cardiovascular, liver and renal diseases;\n* History of hypothyroidism, hyperthyroidism or pheochromocytoma;\n* Signs or symptoms of cardiopathy or angina;\n* History of edema from any etiology;\n* Participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, glucocorticoid or monoamine oxidase inhibitors;\n* Use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months;\n* Dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss;\n* History of surgical treatment for hair loss or presence of shaved scalp;\n* Scalp microinfusion, microneedling or intradermotherapy in the last 3 years;\n* Vaginal or cesarean deliveries 6 months before the inclusion in the study;\n* Drastic modification of habitual diet, as food restrictions or hyperselectivity;\n* Current cancer or history of cancer in the last 5 years;\n* Participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.","50 Years",{"count":105,"type":20},504,[23],"The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.",[27],"2024-02-15",{"date":111,"type":36},"2024-02-16",{"date":113,"type":20},"2025-01",{"date":115,"type":20},"2027-01",{"name":117,"class":43},"EMS"]